Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Peter James O'Dwyer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9302-4073; OpenAlex author ID A5028533192; NIH RePORTER profile ID 1890216. Sources: ClinicalTrials.gov.

Their work

Papers
26 (first author 0, last author 6)
Trials
2 (principal investigator on 2)
Grants
1
Labs led
1
Collaborators
149
Papers, trials and grants by year

2008: 2 trials · 2009: none · 2010: none · 2011: none · 2012: none · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 4 papers · 2020: 3 papers · 2021: 1 paper · 2022: 4 papers, 1 grant · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 26

  1. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Co-author DOI 10.1038/s43018-026-01165-8↗
  2. Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses. Co-author DOI 10.1158/2767-9764.crc-26-0443↗
  3. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-024-49915-5↗
  4. Effect of Stroma-directed Drugs in Combination with Chemotherapy Against Pancreatic Cancer- a Preclinical Study Co-author DOI 10.1101/2024.12.24.630138↗
  5. The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and … Last author DOI 10.1016/j.jgo.2023.101474↗
  6. A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Co-author DOI 10.1186/s13148-022-01367-8↗
  7. Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po.22.00060↗
  8. Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.28127↗
  9. DWI Metrics Differentiating Benign Intraductal Papillary Mucinous Neoplasms from Invasive Pancreatic Cancer: A Study in GEM Models. Co-author DOI 10.3390/cancers14164017↗
  10. THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.28099↗
  11. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Co-author DOI 10.1038/s41416-019-0582-7↗
  12. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-019-0683-3↗
  13. Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-20-0099↗
  14. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. Last author DOI 10.1001/jamaoncol.2019.0684↗
  15. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914915116↗
  16. Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-18-2276↗
  17. Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation. Co-author DOI 10.1200/po.18.00271↗
  18. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. Co-author DOI 10.1007/s00280-017-3494-3↗
  19. A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. Co-author DOI 10.1007/s00280-018-3519-6↗
  20. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2017.209↗
  21. Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Last author DOI 10.1093/annonc/mdw607↗
  22. Locally advanced pancreatic cancer: maybe not so local. Co-author DOI 10.1016/s1470-2045(16)30119-x↗
  23. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Co-author DOI 10.1038/ncomms8686↗
  24. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Co-author DOI 10.1016/j.cell.2014.08.007↗
  25. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally a… Last author DOI 10.1007/s00280-013-2147-4↗
  26. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-13-1320↗

Trials 2

  1. GI-4000 With Adoptive Transfer in Pancreatic Cancer Principal investigator NCT00837135↗
  2. A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreati… Principal investigator NCT01181245↗

Grants 1

  1. Penn Quantitative MRI Resource for Pancreatic Cancer U24CA231858↗

Closest collaborators

The 25 strongest of 149 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mark Alan Rosen · 5 shared papers, 1 shared grant, 2019–2026 · strength 1.27
  2. Rong Zhou · 4 shared papers, 1 shared grant, 2019–2026 · strength 1.16
  3. Thomas Benjamin Karasic · 7 shared papers, 2019–2026 · strength 1.06
  4. Kim A. Reiss · 9 shared papers, 2018–2024 · strength 0.98
  5. Mark H. O’Hara · 7 shared papers, 2018–2024 · strength 0.74
  6. Stephen Pickup · 4 shared papers, 2019–2026 · strength 0.64
  7. Mamta Gupta · 3 shared papers, 2022–2026 · strength 0.54
  8. Jacob Edward Till · 4 shared papers, 2021–2024 · strength 0.51
  9. Erica L. Carpenter · 4 shared papers, 2021–2024 · strength 0.51
  10. Daniel D. Von Hoff · 5 shared papers, 2015–2026 · strength 0.44
  11. Jeffrey A. Drebin · 7 shared papers, 2013–2019 · strength 0.36
  12. Jennifer Rachel Eads · 2 shared papers, 2022–2024 · strength 0.25
  13. Shirsa Udgata · 2 shared papers, 2021–2022 · strength 0.25
  14. Phyllis A. Gimotty · 2 shared papers, 2021–2022 · strength 0.25
  15. Bryson W. Katona · 2 shared papers, 2021–2022 · strength 0.25
  16. Kenneth S. Zaret · 2 shared papers, 2021–2022 · strength 0.25
  17. Jianbo Cao · 2 shared papers, 2019–2022 · strength 0.22
  18. Zev A. Wainberg · 2 shared papers, 2020–2024 · strength 0.22
  19. Ronald M. Evans · 2 shared papers, 2014–2026 · strength 0.21
  20. Elena Gabriela Chiorean · 3 shared papers, 2013–2020 · strength 0.20
  21. Susan M. Domchek · 2 shared papers, 2019–2020 · strength 0.20
  22. Katherine L. Nathanson · 2 shared papers, 2019–2020 · strength 0.20
  23. Shun Yu · 2 shared papers, 2019–2020 · strength 0.20
  24. Harshabad Singh · 1 shared paper, 2026 · strength 0.18
  25. ANDREA C Enzinger · 1 shared paper, 2026 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.